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Abstract Lymphatic filariasis is caused by infection with the 
filarial nematodes Brugia malayi, Brugia timori, Wuchereria 
bancrofti and Onchocerca volvulus which collectively infect about 
200 million persons throughout he world. Protein sequence ho- 
mology analysis of a major nematode antigen suggested that it 
was a class II aminoacyl-tRNA synthetase. The overproduction, 
purifcation and verification that the major B. malayi antigen is 
an asparaginyi-tRNA synthetase is described. 
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1. Introduction 
Nematodes are one of the three groups of helminths that 
parasitize man. According to the World Health Organization 
nematode diseases affect more than one billion persons in var- 
ious geographic areas throughout he world and the filarial 
nematodes Brugia malayi, Brugia timori, Wuchereria bancrofti 
and Onchocerca volvulus, which cause lymphatic filariasis (ele- 
phantiasis) or onchocerciasis (river blindness), affect more than 
200 million persons [1]. 
In the course of immunological studies of filarial parasite 
antigens, the gene encoding an immunodominant 63 kDa pep- 
tide in B. malayi was also found within the genome of another 
major human filarial parasite, O. volvulus the organism which 
causes onchocerciasis [2,3]. When originally described, the de- 
rived amino acid sequence of the B. malayi gene product was 
thought o have no similarity with previously known proteins. 
Subsequent to recognition of a second class of aminoacyl- 
tRNA synthetases in 1990 [4,5], reanalysis of the B. malayi 
antigen sequence revealed the presence of one, and possibly 
two, allowing for a frame-shift error, structural motifs charac- 
teristic of the class II aminoacyl-tRNA synthetases which sug- 
gested that the antigen was an asparaginyl-tRNA synthetase 
[6]. Previously, only a truncated 55 kDa portion of the B. malayi 
peptide had been expressed for immunological studies. The 
missing 8 kDa peptide sequence contained a terminal motif 3 
region characteristic of the class II enzymes required for active 
site formation and aminoacylation activity. We describe here 
the cloning and overexpression f B. malayi antigen as a fusion 
protein with maltose binding protein and the demonstration 
that it has enzymatic activity characteristic of an asparaginyl- 
tRNA synthetase. 
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2. Materials and methods 
2.1. Plasmids, expression and purification 
PolyA enriched RNA was extracted from adult female R malayi 
parasites using standard techniques and 50ng was used to synthesize 
cDNA using reverse transcriptase (Timesaver eDNA Synthesis, Phar- 
macia, Inc.) The resulting eDNA was used as template for amplification 
of R malayi antigen gene using two gene specific oligonucleotide 
primers: 
5': ATGACTGTTTATATTTGTCCAGAAACTGGAGAT 3" and 
5': TTGAATTCTTATGGGACACATCGACCAACAAAGCGAGG 3' 
with 30 cycles of amplification using the following thermocycler pa- 
rameters: hot start at 92°C for 60 s, denaturation: 95°C for 30 s, 
annealing: 55°C for 30 s, primer extension: 72°C for 90 s, terminal 
extension: 5min at 72°C. PCR products were subcloned using the TA 
cloning system (In Vitrogen, Inc.) and eDNA inserts of the correct size 
and orientation were identified in the TA cloning vector by restriction 
fragment length polymorphism and DNA sequence analysis. 
A full-length cDNA was subcloned into the plasmid pMALc (New 
England Biolabs) for large scale overproduction f the recombinant 
protein as a fusion protein with the 42 kDa maltose binding protein. 
Growth media in a 20 litre fermenter was seeded with cultures of the 
E. coli Invc~F', a strain harboring the plasmid containing the filarial 
antigen eDNA, and grown at 30°C. From this culture, induced with 
IPTG, 40 grams of bacterial cell paste was obtained. A series of purifi- 
cation steps which included anion-exchange chromatography (DEAE- 
Sepharose CL-6B, Pharmacia), affinity chromatography (amylose 
resin), preparative Factor Xa (New England Biolabs) cleavage of the 
maltose binding protein fusion product, followed by anion exchange 
chromotography b FPLC on Mono Q (Pharrnacia) to isolate the 
recombinant antigen protein (63 kDa). 
2.2. Aminoacylation assays 
Enzymatic activity was measured by the incorporation i to unfrac- 
tionated tRNA of ~4C-labelled amino acids. Protein samples (10/11) 
were added to 40 ~tl Tris (64 mM)-HCI buffer pH 7.6 containing: 0.5 
mM spermidine, 5 mM disodium ATP, 500/1g unfractionated E. coli or 
brewers yeast RNA or 250/~g calf liver tRNA and labelled amino acid. 
These were 0.1 mM L-[J4C]asparagine (98 cpm/pmol), 0.1 mM L-[14C]as- 
partic acid (100 cpm/pmol) and 1/~Ci U-[J4C]protein hydrolysate. All 
tRNAs were from Boehringer and all labelled amino acids from Amer- 
sham. After incubation for 15 rain at 37°C, the reactions were quenched 
with 50/11 of 5% (w/v) TCA, and the mixture was spotted onto a 
Whatman GF/A glass fibre filter. The filter was then washed 3 times 
with 5% TCA, and subsequently with ethanol, ethanol:ether, ether, 
dried and counted for radioactivity. 
3. Results 
Fig. 1A shows an ethidium bromide stained agarose gel of 
the product obtained by PCR using B. malayi cDNA and the 
two putative aminoacyl-tRNA synthetase primers. This incor- 
porated into the plasmid pMALc could be used to express a 
protein of Mr 105K on SDS-PAGE which corresponded to the 
fusion protein between maltose binding protein and the 63 kDa 
protein in E. coli (InvaF'). After a preliminary fractionation of 
the bacterial cell extracts by anion-exchange chromatography 
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Fig. 1. Panel A. Ethidium bromide stained 1% agarose gel demonstrat- 
ing PCR products obtained by reverse transcriptase PCR using AARS 
specific oliogonucleotide primers. Panel B. Coomassie brilliant blue- 
stained SDS-PAGE 10% gel showing purified recombinant B. malayi 
antigen (63kDa) after factor Xa cleavage. 
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Fig. 2. Asparagine incorporation i to tRNAs catalysed by by the 
B. malayi antigen fusion protein with maltose binding protein at various 
dilution of an approximately 3.8 mg/ml solution. []E. coli tRNA, 
v yeast RNA, [] calf liver tRNA. 
the fusion protein was further purified by affinity chromatogra- 
phy on amylose resin. SDS-PAGE and activity measurements 
for asparagine and aspartic acid with E. coli tRNA for the 
ion-exchange fractionation step showed separation between the 
host enzymatic activities and the expressed 105 kDa protein. 
The fusion protein isolated by affinity chromatography was 
assayed with a labelled mixture of amino acids (protein hy- 
drolysate), aspartic acid and asparagine using tRNAs from 
three different sources. Amino acid incorporation i to tRNA 
was only found with asparagine with low incorporation i to 
E. coli, moderate into yeast and high into calf liver tRNAs (Fig. 
2). Considering the results with calf liver tRNA with the dilu- 
tion series of the purified fusion protein (initial concentration 
ca. 3.8 mg/ml), at 1:1000 an approximate asparaginyl-tRNA 
synthetase specific activity of I/~ol/mg can be calculated under 
conditions in which tRNA does not appear to be limiting (Fig. 
2). That fusion with maltose binding protein need not inhibit 
aminoacylation activity of aminoacyl-tRNA synthetases has 
already been observed in this laboratory with seryl-tRNA syn- 
thetase (H~irtlein, unpublished results). After Factor Xa cleav- 
age, fractionation by FPLC led to a product with an Mr of 63 
kDa which appeared to be at least 95% pure as judged by 
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SDS-PAGE (Fig. 1B). This material when assayed under simi- 
lar conditions to that for the fusion protein i.e. a solution of 2.2. 
mg/ml diluted 1 : 1000 used in the aminoacylation of calf liver 
tRNA (see section 2.2) incorporated 35 pmol asparagine which 
corresponds to a specific activity under the assay conditions of 
1.5/.tmol/mg. 
4. Discussion 
The new DNA sequence data for the B. malayi asparaginyl- 
tRNA synthetase [3] demonstrated a discrepancy with the pre- 
viously published sequence [2], which produced a frameshift 
that obscured a typical class II aminoacyl-tRNA synthetase 
motif 2 sequence (RAEK....SRTRRH) at amino acids 314-324 
[6]. Although the original observation that, allowing for a frame 
shift error, the sequence of the B. malayi antigen was possibly 
an asparaginyl-tRNA synthetase [6], the sequence of the highly 
homologous O. volvulus antigen suggested that this might be an 
aspartyl-tRNA synthetase [3]. The results presented above 
demonstrate hat the B. malayi antigen is an asparaginyl-tRNA 
synthetase ffectively aminoacylating tRNA from eucaryotic 
sources and can be purified to a specific activity similar to that 
found e.g. seryl-tRNA synthetase from bovine liver [7]. Align- 
ment of known asparaginyl-tRNA synthetase sequences with 
those of both the B. malayi antigen demonstrate conservation 
of both active site motifs and other conserved sequences (Fig. 
3) are consistent with this observation. 
The fact that the B. malayi peptide was originally identified 
<<<<<<<<<<<< Mof i f  2 >>>>>>>>>>>> 
Antbm LGDVFHLHCSYRAZKSRTR~JNLAEYAHV~AECPF I  341 
Nrsscm LSRCWTLSPCFRA~KSDTPRI l LSEFWMLEV]CMCTV 262 
Nrsscc  LGDVYT IQESF I~KSHTI~LSEYTHIRAZLAFL  350 
Nrs t t  FAKVYTFGPTFRAZRBKTRILqLLEFWMVEpEVAFM 227 
Nrsec  LSK IYTFGPTF Iq /~NNTS~LAZFWMLEPEVAFA 257 
Nrsh i  LSK IYTFGPTFRAENNN~TRI ILAEFWMV~pEVAFA 268 
Antbm 
Nrsscm 
Nrsscc  
Nrs t t  
Nrsec  
Nrsh i  
KA~"~MQRDAQDNTLTESVDLLMP-GVGE~VGGSMRIWKFDELSKAF  486 
KPF%"MKQNSTPDDTVGCFDLLVP GMGEXIGGSLREDDYDKLCREM 431 
KS I~f f t lKRCSDDPRVTESVDVLMP-NVGEZTGGSMI~IDDMDELMAGF 495 
~AI~EPDPEDPELVLNDDLLRPEGYGEZI~SQRIHDLELLRRKI  375 
F .AFYMRLN-EDGKTVAA~VLAP-G IGE~IGGSQREERLDVLDERM 407 
KAF%"MRLN-DDEKTVAAMDVLAP-G IGEZIGGSQREERLEVLDKRM 418 
Antbm 
Nrsscm 
Nrsscc  
Nrs t t  
Nrsec  
Nrsh i  
<<<<<<<<<<<<<<< Mot i f  3 >>>>>>>>>>>>>>> 
WYLDQRLYGTCPHGGYGLGLERF ICWLTNTNHIRDVCLYPR 538 
WYVSLRKEGSAPMGQFGLGFERF ISYLYGNHN[KDAIPFYR 484 
WFIDQRKYGTCPHGGYGIGTF JR ILAWLCDRFTVRDCSLYPR 547 
WYLDLRRFGSVPHSGFGLGL~TVAWICGLA~JREAIPFPR 427 
WXRDLRRYGTVPHSGFGLGF~LIAYVTGVQ~JRDVIPFPR 458 
WYRDLRKYGSVPHSGFGLGF I~L IV55/TGVQNIRDVIPFPR 470 
Antbm : ant igen  of Brugia malayi 
Nrsscm : Saccharomyces cerevisiae mitochodr la l  
Nrsscc  : Saccharomyces cerevisiae cytop lasmic  
Nrs t t  - Thermus [hermophilus. 
Nrsec  - Escheriehla coli 
Nrsh i  - Haemophilus influenzae 
Fig. 3. Alignment of asparaginyl-tRNA synthetase conserved sequences 
of the enzymes from E. coli (Nrsec) [13], Thermus thermophilus (Nrstt) 
[14], Haemophilus influenzae(Nrshi) [15] and the putative mitochondrial 
(Nrsscm) [16] and cytoplasmic (Nrsscc) [17] from Saccharomyces cer- 
vesiae (Nrsscm), with the sequence of the B. malayi antigen Antbm. The 
published DNA sequences for Antbm [2] for motif 2 has been corrected 
for frame shift errors (M. Kron, unpublished results). Conserved resi- 
dues for the five proteins are in bold type. 
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as strongly immunogenic, is understandable in view of what is 
known about AARS antigenicity in other species. In the group 
of human autoimmune diseases known as the idiopathic inflam- 
matory myopathies, antibodies have been identified against 
several human class II aminoacyl-tRNA synthetases; histidyl-, 
threonyl-, alanyl- and glycyl-tRNA synthetases [8,9]. Anti- 
AARS antibodies effectively inhibit enzyme aminoacylation 
activity in vitro, and are able to immunoprecipitate th ir respec- 
tive cognate tRNAs [10]. Given the high level of expression of 
message ncoding this enzyme in B. malayi [2], it is possible to 
speculate on the demand for asparaginyl-tRNA synthetase ac- 
tivity in the adult female parasite. Class II aminoacyl-tRNA 
synthetases also function in the production of adenylated nucle- 
otides, in particular the adenylated nucleotide Ap4A which may 
play a variety of biological roles as signal molecules, regulating 
both gene expression and enzyme activity [11,12]. Since consid- 
erable metabolic effort of the adult female parasite is devoted 
to nutrition and production of viable embryos and larvae, it is 
conceivable that the high level of asparaginyl-tRNA synthetase 
expression reflects unusual metabolic demands associated with 
larval maturation. 
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